BioSpace News Archive

- Engages with Scientific, Governmental and Regulatory Agencies - Targeting Q4 2020 Initiation of an Adaptive Phase 2 Trial [23-June-2020] CRANBURY, N.J. , June 23, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanoco

- Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in WM - The National Comprehensive Cancer Network® (NCCN®) recommends IMBRUVICA, with or without rituximab, for patients with WM, including Category 1, Preferred for Primary Therapy for WM - IMBRUVICA has been used to treat ne

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM ™ platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients. The GuardantINFORM platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partne

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced its participation in the Noble Capital Markets c-suite webinar series. The webinar was led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D., with participation by Steven M. Fruchtman, M.D., President and

Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that Andrei Floroiu, Chief Executive Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:25 am ET H.C. Wainwright Virtual Fireside Chat Series Date: Thursday, June 25 t

The New Codes Reflect MyoStrain’s Unique Clinical Value in Diverse Applications Across Cardiac and Cancer Care

Study Shows Low Incidence of Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Reducing Potential Complications Associated with Implanted Markers

Bendit Technologies, an industry leader in the development of steerable microcatheters, announced that Richard Cappetta has been appointed as its Chairman of the Board.

TYME-18 leverages unique metabolism of cancer to create an intra-tumoral treatment for inoperable cancers

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through person